Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 139
Filter
1.
Eur Rev Med Pharmacol Sci ; 24(19): 10051-10053, 2020 10.
Article in English | MEDLINE | ID: mdl-33090410

ABSTRACT

OBJECTIVE: Long-term survival of patients with neonatal-onset carbamoyl-phosphate synthetase 1 deficiency (CPS1D), an autosomal recessive disorder characterized by repeated, life-threatening hyperammonemia, is rare. We describe the diagnosis and clinical management of a teenager with neonatal-onset CPS1D who did not undergo therapeutic liver transplantation. CASE REPORT: Following emergent neonatal therapy, the patient was diagnosed with CPS1D based on clinical, radiological, biochemical and genetic analyses. Her clinical course, neurobehavioral development and therapeutic interventions are presented and discussed. RESULTS: Born from nonconsanguineous parents, the proband underwent phototherapy for neonatal jaundice, associated with acute encephalopathy, apnea and cerebral edema. Based on blood and urinary biochemical abnormalities, neonatal-onset CPS1D was diagnosed. Her hyperammonemia was corrected by hemodialysis, followed by sodium benzoate, L-arginine, levocarnitine and protein-free diet therapy. Because of a relapse and persistent neurobehavioral regression by age 1, a planned liver transplantation was cancelled. At age 10, sodium phenylbutyrate was substituted as ammonia scavenger. Genetic testing revealed compound heterozygote c.2359C>T (R787X) and c.236+6T>C variants of CPS1, confirming her diagnosis. Despite severe neurological sequelae, the patient is 16 and in stable condition. CONCLUSIONS: Our case suggests that early hemodialysis and pharmacologic interventions for acute neonatal hyperammonemia can improve the prognosis of patients with neonatal-onset CPS1D.


Subject(s)
Arginine/therapeutic use , Brain Diseases, Metabolic/therapy , Carbamoyl-Phosphate Synthase I Deficiency Disease/therapy , Carnitine/therapeutic use , Hyperammonemia/therapy , Phenylbutyrates/therapeutic use , Renal Dialysis , Sodium Benzoate/therapeutic use , Female , Humans , Infant, Newborn
2.
Diabetes Metab ; 45(4): 369-374, 2019 09.
Article in English | MEDLINE | ID: mdl-30391714

ABSTRACT

AIMS: Our aim was to evaluate the acute effect of eating sweet snacks at different times of day on glycaemic parameters in young women without diabetes. METHODS: In this randomized controlled three-treatment crossover study, 17 women [(means ± SD) age: 21.2 ± 0.8 years, BMI: 20.7 ± 2.5 kg/m2, HbA1c: 36 ± 2 mmol/mol (5.1 ± 0.2%)] wore flash (continuous) glucose monitoring systems for 7 days. Each participant consumed identical test meals on days 4, 5 and 6, but consumed sweet snacks (baked cake: 498 kcal; 53.6 g of carbohydrate, 8.0 g of protein, 28.0 g of fat) at 12:30 (post-lunch), 15:30 (mid-afternoon) and 19:30 (post-dinner), respectively, on each of those days. Daily glycaemic parameters on those 3 days of snacking at different times of day were compared within-participant. RESULTS: The mean amplitude of glycaemic excursions (3.54 ± 0.32 vs. 2.73 ± 0.20 mmol/L; P < 0.05), standard deviation of glucose (1.20 ± 0.11 vs. 0.92 ± 0.07 mmol/L; P < 0.05), incremental area under the curve (IAUC) for glucose at 12:00-07:00 (986 ± 89 vs. 716 ± 88 mmol/L × min; P < 0.05) and IAUC at 07:00-10:00 the next day (141 ± 17 vs. 104 ± 12 mmol/L × min; P < 0.05) when the snack was eaten post-dinner were all significantly higher than with mid-afternoon snacking. CONCLUSION: Eating sweet snacks post-dinner should be avoided because it worsens glucose excursions as well as postprandial glucose levels after both dinner and the following day's breakfast in young healthy (non-diabetic) women.


Subject(s)
Blood Glucose/drug effects , Dietary Sugars/pharmacology , Postprandial Period/drug effects , Snacks/physiology , Adult , Blood Glucose/metabolism , Blood Glucose Self-Monitoring/methods , Circadian Rhythm/physiology , Cross-Over Studies , Female , Healthy Volunteers , Humans , Time Factors , Young Adult
3.
Diabetes Metab ; 44(6): 482-487, 2018 12.
Article in English | MEDLINE | ID: mdl-30054154

ABSTRACT

AIMS: Our aim was to explore the acute effects of consuming snacks at different times on glucose excursions in patients with type 2 diabetes (T2D). METHODS: Seventeen patients with T2D [means±SD: age 67.4±9.4-years; BMI 23.5±3.1kg/m2; HbA1c 55±6mmol/mol (7.2±1.0%)] were randomly assigned in this crossover study. Each participant wore a continuous glucose monitoring device for 4 days and consumed identical test meals on the second and third days, comprising breakfast at 0700h, lunch at 1200h and dinner at 1900h. Half the participants consumed 75kcal biscuits at 1230h (just after lunch) on the second day and at 1530h (mid-afternoon) on the third day, while the other half consumed snacks at the same times, but vice versa. Each patient's glucose parameters were compared against baseline for the 2days of snacking at different times of day. RESULTS: Consuming snacks in the mid-afternoon led to significantly lower mean amplitudes of glycaemic excursions (mean±SEM: 5.19±0.48 vs. 6.90±0.69mmol/L, P<0.01; standard deviation: 1.75±0.17 vs. 2.16±0.21mmol/L, P<0.01) and incremental areas under the curve for glucose after dinner (479±76 vs. 663±104mmol/L per min, P<0.01) compared with snacking just after lunch, whereas mean glucose levels did not differ over the 2days. CONCLUSION: These results suggest that consuming snacks well separated from lunch may be an effective way to suppress postprandial glucose levels and glycaemic excursions.


Subject(s)
Blood Glucose/analysis , Diabetes Mellitus, Type 2/blood , Eating/physiology , Snacks , Aged , Blood Glucose Self-Monitoring , Cross-Over Studies , Female , Glycated Hemoglobin/analysis , Humans , Lunch , Male , Middle Aged , Postprandial Period/physiology
4.
Eur Rev Med Pharmacol Sci ; 20(5): 919-22, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27010151

ABSTRACT

Long term survival for the cases of trisomy 13 into over a first decade is very rare. We reported here the case of a 14-year-old male karyotype with full type of trisomy 13. In this clinical phenomenon, the case had typical facial, finger and limb anomalies for trisomy 13. Arterial septal defect and patent ductus arteriosus were recognized using ultrasonography after birth. Major cerebral malformation such as holoprosencephaly or cerebellar hypoplasia were also not revealed. After 5 months of his age, artificial ventilation therapy for dyspnea associated with laryngomalacia was required. A tracheotomy was performed at 6 months of his age. After 12 years old, intractable partial epilepsy was recognized. For his partial seizures, a treatment with a combination of two anti-epileptic drugs, valproic acid and levetiracetam, were advised. Now he is alive for 14-years-old and he is the 4th longest surviving patient with full karyotype of trisomy 13.


Subject(s)
Chromosome Disorders , Trisomy , Adolescent , Chromosome Disorders/complications , Chromosome Disorders/diagnostic imaging , Chromosomes, Human, Pair 13/diagnostic imaging , Ductus Arteriosus, Patent/complications , Ductus Arteriosus, Patent/diagnostic imaging , Humans , Karyotype , Male , Survivors , Trisomy 13 Syndrome
6.
Curr Mol Med ; 15(3): 265-74, 2015.
Article in English | MEDLINE | ID: mdl-25817861

ABSTRACT

Piccolo (PCLO) inhibits methamphetamine-induced neuropharmacological effects via modulation of dopamine (DA) uptake and regulation of the transport of synaptic vesicles in neuronal cells. Clinical studies have recently suggested that the single nucleotide polymorphism (SNP) rs13438494 in the intron 24 of the PCLO gene is associated with psychiatric disorder, in the meta-analysis of GWAS. Therefore, in this study, we attempted to evaluate the possible role of the PCLO SNP in the mechanisms of uptake of monoamines. To characterize rs13438494 in the PCLO gene, we constructed plasmids carrying either the C or A allele of the SNP and transiently transfected them into SH-SY5Y cells to analyze genetic effects on the splicing of PCLO mRNA. The C and A allele constructs produced different composition of the transcripts, indicating that the intronic SNP does affect the splicing pattern. We also transfected DA and serotonin (5-hydroxytryptamine; 5- HT) transporters into cells and analyzed their uptakes to elucidate the association to psychiatric disorders. In the cells transfected with the C allele, both the DA and 5-HT uptake were enhanced compared to the A allele. We also conducted a clinical study, in order to clarify the genetic associations. PCLO rs13438494 exhibits a relationship with the symptoms of drug dependence or related parameters, such as the age of first exposure to methamphetamine, eating disorders, tobacco dependence and fentanyl requirement. Our findings suggest that rs13438494 is associated with drug abuse and contributes to the pathogenesis of psychiatric disorders via modulation of neurotransmitter turnover.


Subject(s)
Amphetamine-Related Disorders/genetics , Anorexia/genetics , Cytoskeletal Proteins/genetics , Dopamine/metabolism , Neuropeptides/genetics , Serotonin/metabolism , Age of Onset , Analgesics, Opioid/therapeutic use , Fentanyl/therapeutic use , Genetic Predisposition to Disease , Genome-Wide Association Study , HEK293 Cells , Humans , Introns , Orthognathic Surgery , Polymorphism, Single Nucleotide
9.
Domest Anim Endocrinol ; 43(2): 198-211, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22560178

ABSTRACT

The bovine corpus luteum (CL) is a unique, transient organ with well-coordinated mechanisms by which its development, maintenance, and regression are effectively controlled. Angiogenic factors, such as vascular endothelial growth factor A and basic fibroblast growth factor, play an essential role in promoting progesterone secretion, cell proliferation, and angiogenesis. These processes are critically regulated, through both angiogenic and immune systems, by the specific immune cells, including macrophages, eosinophils, and neutrophils, that are recruited into the developing CL. The bovine luteolytic cascade appears to be similar to that of general acute inflammation in terms of time-dependent infiltration by immune cells (neutrophils, macrophages, and T lymphocytes) and drastic changes in vascular tonus and blood flow, which are regulated by luteal nitric oxide and the vasoconstrictive factors endothelin-1 and angiotensin II. Over the period of maternal recognition of pregnancy, the maternal immune system should be well controlled to accept the semiallograft fetus. The information on the presence of the developing embryo in the genital tract is suggested to be transmitted to the ovary by both the endocrine system and the circulating immune cells. In the bovine CL, the lymphatic system, but not the blood vascular system, is reconstituted during early pregnancy, and interferon tau from the embryo could trigger this novel phenomenon. Collectively, the angiogenic and vasoactive factors produced by luteal cells and the time-dependently recruited immune cells within the CL and their interactions appear to play critical roles in regulating luteal functions throughout the life span of the CL.


Subject(s)
Cattle/physiology , Corpus Luteum/physiology , Immune System/physiology , Luteolysis/physiology , Neovascularization, Physiologic/physiology , Neutrophils/immunology , Angiogenic Proteins/physiology , Angiotensin II/physiology , Animals , Corpus Luteum/blood supply , Corpus Luteum/growth & development , Endothelin-1/physiology , Eosinophils/immunology , Female , Immune System/cytology , Macrophages/immunology , Nitric Oxide/physiology , Pregnancy , Vascular Endothelial Growth Factor A/physiology
10.
J Chem Phys ; 131(16): 164309, 2009 Oct 28.
Article in English | MEDLINE | ID: mdl-19894949

ABSTRACT

Excitation (total ion yield) and de-excitation (resonant photoemission) spectra have been measured in the Si 1s photoexcitation region of the F(3)SiCH(2)CH(2)Si(CH(3))(3) molecule using monochromatized undulator radiation. Theoretical calculations within the framework of density functional theory have reproduced the observed total ion yield spectrum very well. The first peak at the lowest photon energy, coming from Si 1s excitation at the trimethyl side into a vacant orbital, induces spectator Auger decays in which the excited electron remains in its valence orbital. The second peak produced through excitation of Si 1s electron at the trifluoride side generates resonant Auger decays in which the excited valence electron remains predominantly also in the valence orbital or is partly shaken up into higher Rydberg orbitals. The third peak generated through Si 1s excitation at the trifluoride side produces resonant Auger decays in which the excited Rydberg electron remains or is partly shaken down to a lower lying valence molecular orbital. These findings exhibit a clear distinction between resonant Auger decays following photoexcitation of Si 1s electrons under different chemical environments.

11.
Mol Psychiatry ; 13(4): 349, 451-63, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18195717

ABSTRACT

Dopamine transporter (DAT) internalization is a mechanism underlying the decreased dopamine reuptake caused by addictive drugs like methamphetamine (METH). We found that Piccolo, a presynaptic scaffolding protein, was overexpressed in the nucleus accumbens (NAc) of the mice repeatedly administrated with METH. Piccolo downexpression by antisense technique augmented METH-induced behavioral sensitization, conditioned reward and synaptic dopamine accumulation in NAc. Expression of Piccolo C2A domain attenuated METH-induced inhibition of dopamine uptake in PC12 cells expressing human DAT. Consistent with this, it slowed down the accelerated DAT internalization induced by METH, thus maintaining the presentation of plasmalemmal DAT. In immunostaining and structural modeling Piccolo C2A domain displays an unusual feature of sequestering membrane phosphatidylinositol 4,5-bisphosphate, which may underlie its role in modulating DAT internalization. Together, our results indicate that Piccolo upregulation induced by METH represents a homeostatic response in the NAc to excessive dopaminergic transmission. Piccolo C2A domain may act as a cytoskeletal regulator for plasmalemmal DAT internalization, which may underlie its contributions in behavioral plasticity.


Subject(s)
Behavior, Animal/physiology , Cytoskeletal Proteins/physiology , Dopamine Plasma Membrane Transport Proteins/metabolism , Neuropeptides/physiology , Analysis of Variance , Animals , Behavior, Animal/drug effects , Conditioning, Operant/drug effects , Conditioning, Operant/physiology , Dopamine/metabolism , Dopamine Uptake Inhibitors/pharmacology , Humans , Methamphetamine/pharmacology , Mice , Mice, Inbred C57BL , Microdialysis/methods , Motor Activity/drug effects , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Oligodeoxyribonucleotides, Antisense/pharmacology , PC12 Cells , Phosphatidylinositol 4,5-Diphosphate/metabolism , Protein Structure, Tertiary , Protein Transport/drug effects , Protein Transport/physiology , Rats , Transfection
12.
Genet Couns ; 18(3): 303-8, 2007.
Article in English | MEDLINE | ID: mdl-18019371

ABSTRACT

The prognosis of trisomy 18 is lethal, but recently some long-term survival cases have been recognized. We report here the mortality rate of trisomy 18 based on our hospital data and sporadically published reports in Japan. We collected the 7 previously published reports of mortality and 31 cases from our hospital data with trisomy 18. Our data pool comprised a total of 179 cases of trisomy 18 from 8 institutions. The mortality rates within 24 hours, 7, 28, 60, 180, and 365 days from birth were 14.84% (19/128), 31.01% (40/129), 56.25% (72/128), 64.08% (66/103), 82.17% (106/129), and 90.90% (140/154), respectively. Fourteen of the 154 patients (9.09%) survived for more than 1 year. The Kaplan-Meier survival curves from 78 patients of 5 institutes suggest that trisomy 18 children who have survived over 7 months after birth may have a high probability of long-term survival. We should recognize not only that about 50% of infants with trisomy 18 die within 1 month after birth, but also that about 10% of patients survive over 1 year in Japan. These findings comprise Asia's first clinical statistics concerning trisomy 18, in which the data were collected from multiple institutions. This evidence is valuable in order to perform genetic counseling concerning the natural history of trisomy 18 not only in Japan but also in other countries.


Subject(s)
Chromosomes, Human, Pair 18 , Trisomy/genetics , Genetic Counseling , Humans , Japan/epidemiology , Karyotyping , Survival Analysis , Survivors , Trisomy/physiopathology
13.
Neuroscience ; 146(1): 50-9, 2007 Apr 25.
Article in English | MEDLINE | ID: mdl-17317018

ABSTRACT

Tissue plasminogen activator (tPA) plays a key role in neuroplasticity. We have recently demonstrated that the tPA-plasmin system is involved in the rewarding effects of drugs of abuse by regulating the release of dopamine in the nucleus accumbens. In the present study, we investigated whether tPA is involved in the reinforcing properties of morphine in a paradigm of drug self-administration. Eight-week-old tPA knockout and wild-type control mice were subjected to a single 24-h session of morphine self-administration under a fixed ratio (FR) 2 or a progressive ratio (PR) schedule of reinforcement after eight daily 30-min sessions of nose-poke training. tPA knockout mice responded significantly more often for morphine self-administration in a dose-dependent manner as compared with wild-type control mice. Under the PR schedule of morphine reinforcement, however, tPA knockout mice showed a lower breaking point than wild-type control mice. There was no significant difference in food-reinforced operant behavior, breaking points to food pellets, and saline self-administration between the two genotypes. The increased responding in tPA knockout mice under the FR2 schedule was significantly attenuated by the dopamine D1 receptor antagonist SCH23390 (0.3 mg/kg), whereas SCH23390, at a dose range of 0.03-2.0 mg/kg, demonstrated biphasic effects on morphine self-administration in wild-type control mice. Our findings suggest that the reinforcing effects of morphine are reduced in tPA knockout mice. Modulation of the tPA system in the brain may be a potential target against drugs of abuse.


Subject(s)
Conditioning, Operant/drug effects , Morphine/administration & dosage , Narcotics/administration & dosage , Reinforcement, Psychology , Tissue Plasminogen Activator/deficiency , Analysis of Variance , Animals , Behavior, Animal/drug effects , Benzazepines/pharmacology , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Exploratory Behavior/drug effects , Food , Male , Mice , Mice, Knockout , Reinforcement Schedule , Self Administration/methods
14.
Transplant Proc ; 37(5): 2290-2, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15964401

ABSTRACT

Human marrow stromal cells (hMSCs) are an attractive source for autologous cell and gene therapies. In this study, we developed a highly efficient transfection method for hMSCs. Although they tend to show efficient gene delivery, nonviral vectors offer several advantages over viral vectors for gene therapies. They are inexpensive to produce and suitable to adopt particularly with respect to little or no specific immune responses; they are simple to use; they entail easier large-scale production; and they have a high degree quality control. hMSCs and rat marrow stromal cells were transfected with the plasmid pEGFP-N1 that encoded a green fluorescent protein component by using two nonviral methods: nucleofection and electroporation. Nucleofection provided a much better rate of transfer than electroporation particularly in hMSCs.


Subject(s)
Bone Marrow Cells/cytology , Stromal Cells/physiology , Transfection/methods , Animals , Cytological Techniques , Genes, Reporter , Green Fluorescent Proteins/analysis , Green Fluorescent Proteins/genetics , Humans , Plasmids , Rats , Recombinant Proteins/analysis , Stromal Cells/cytology
15.
Pediatr Cardiol ; 25(2): 154-6, 2004.
Article in English | MEDLINE | ID: mdl-14681740

ABSTRACT

We present a neonatal case with intractable atrial flutter that did not respond to digitalization and electrical cardioversion. Intravenous flecainide administration completely resolved the atrial flutter. Proarrhythmic effects were not induced by flecainide administration. Although the efficacy of flecainide for atrial flutter during the infantile or childhood period is low, intravenous flecainide is worth consideration as a treatment for atrial flutter, even in intractable cases as described here, during the neonatal period.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Atrial Flutter/congenital , Atrial Flutter/therapy , Flecainide/therapeutic use , Anti-Arrhythmia Agents/administration & dosage , Atrial Flutter/diagnosis , Atrial Flutter/physiopathology , Cardiac Pacing, Artificial , Digoxin/therapeutic use , Echocardiography, Doppler, Color , Electric Countershock , Electrocardiography , Female , Flecainide/administration & dosage , Heart Conduction System/abnormalities , Heart Conduction System/diagnostic imaging , Heart Conduction System/physiopathology , Heart Rate/drug effects , Humans , Infant, Newborn , Infusions, Intravenous , Pregnancy , Pregnancy Complications, Cardiovascular/diagnosis , Pregnancy Complications, Cardiovascular/physiopathology , Pregnancy Complications, Cardiovascular/therapy , Stroke Volume/drug effects , Ultrasonography, Prenatal
16.
Neuroscience ; 119(2): 399-419, 2003.
Article in English | MEDLINE | ID: mdl-12770555

ABSTRACT

Amyloid beta, the major constituent of the senile plaques in the brains of patients with Alzheimer's disease, is cytotoxic to neurons and has a central role in the pathogenesis of the disease. We have previously demonstrated that potent antioxidants idebenone and alpha-tocopherol prevent learning and memory impairment in rats which received a continuous intracerebroventricular infusion of amyloid beta, suggesting a role for oxidative stress in amyloid beta-induced learning and memory impairment. To test the hypothesis, in the present study, we investigated alterations in the immunoreactivity of endogenous antioxidant systems such as mitochondrial Mn-superoxide dismutase, glutathione, glutathione peroxidase and glutathione-S-transferase following the continuous intracerebroventricular infusion of amyloid beta for 2 weeks. The infusion of amyloid beta (1-42) resulted in a significant reduction of the immunoreactivity of these antioxidant substances in such brain areas as the hippocampus, parietal cortex, piriform cortex, substantia nigra and thalamus although the same treatment with amyloid beta (40-1) had little effect. The alterations induced by amyloid beta (1-42) were not uniform, but rather specific for each immunoreactive substance in a brain region-dependent manner. These results demonstrate a cytological effect of oxidative stress induced by amyloid beta (1-42) infusion. Furthermore, our findings may indicate a heterogeneous susceptibility to the oxidative stress produced by amyloid beta.


Subject(s)
Amyloid beta-Peptides/toxicity , Brain/drug effects , Glutathione Peroxidase/metabolism , Glutathione Transferase/metabolism , Glutathione/metabolism , Peptide Fragments/toxicity , Superoxide Dismutase/metabolism , Animals , Blotting, Western , Brain/metabolism , Brain/ultrastructure , Densitometry/methods , Drug Administration Routes/veterinary , Immunohistochemistry/methods , Infusion Pumps , Male , Rats , Rats, Wistar , Time Factors
17.
Metabolism ; 51(11): 1377-80, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12404182

ABSTRACT

To clarify the longitudinal metabolic process of bone growth in children, we observed the relationship between the level of serum osteocalcin (OC), a marker of bone metabolism, and growth velocity in 10 prepubertal patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency and 9 prepubertal patients with nonendocrine short stature (NESS), but no major hormonal abnormalities influencing bone metabolism. Observations were made every 6 months over a 7-year period. In patients with CAH who exhibited a wide variation in growth velocity during the course of the investigation, the levels of OC fluctuated over a wide range, suggesting metabolically variable bone growth. In contrast, in patients with NESS who exhibited a relatively stable growth velocity, the OC level remained within a narrow range, suggesting metabolically stable bone growth. The meaning of such divergent metabolic processes of bone growth observed in CAH and NESS and its relationship to actual bone structure or bone intensity should be further investigated.


Subject(s)
Adrenal Hyperplasia, Congenital/physiopathology , Bone Development , Growth Disorders/physiopathology , Adolescent , Adrenal Hyperplasia, Congenital/blood , Adrenal Hyperplasia, Congenital/enzymology , Child , Child, Preschool , Female , Growth Disorders/blood , Growth Disorders/etiology , Humans , Male , Osteocalcin/blood , Prospective Studies , Steroid 21-Hydroxylase/metabolism
18.
Neurotoxicol Teratol ; 24(5): 695-701, 2002.
Article in English | MEDLINE | ID: mdl-12200200

ABSTRACT

Diabetes is known to be one of the risk factors for dementia; however, neuropathic changes in the brain of patients with the disease have not been completely revealed. So in the present study, we investigated the brain function of rats with diabetes induced by streptozotocin (STZ), one of the most commonly used animal models for diabetes. In the diabetic rats, immediately working memory performance was impaired in the Y-maze task and neuronal cytoskeleton proteins such as calbindin, synaptophysin, and syntaxin were reduced. Furthermore, morphological observation by Golgi staining showed a decrease in the number of basal dendrites and abnormality of spine structure. Next, we measured the content of brain-derived neurotrophic factor (BDNF) in the diabetic brain, because BDNF is one of the essential proteins for the maintenance of neuronal functions including synapse function and neuronal transmissions. In the diabetic brains, both protein and mRNA levels of BDNF were severely reduced. These results suggest that, in diabetes, synapse dysfunction is, at least in part, caused by a failure of BDNF synthesis in the brain.


Subject(s)
Brain-Derived Neurotrophic Factor/deficiency , Brain/metabolism , Dendrites/metabolism , Diabetic Neuropathies/metabolism , Animals , Brain/pathology , Brain/physiopathology , Brain-Derived Neurotrophic Factor/genetics , Cytoskeletal Proteins/deficiency , Dendrites/pathology , Diabetes Mellitus, Experimental/complications , Diabetic Neuropathies/pathology , Diabetic Neuropathies/physiopathology , Disease Models, Animal , Humans , Male , Memory Disorders/etiology , Memory Disorders/metabolism , Memory Disorders/physiopathology , Nerve Degeneration/etiology , Nerve Degeneration/metabolism , Nerve Degeneration/pathology , Rats , Rats, Wistar
19.
J Neurosci Res ; 66(3): 369-76, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11746354

ABSTRACT

The effects of transforming growth factor (TGF)-beta1 on expression of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, TrkB, in neurons cultured from the cerebral cortex of 18-day-old embryonic rats were examined. BDNF mRNA was significantly increased from 24-48 hr after the TGF-beta1 treatment over 20 ng/ml. Accumulation of BDNF protein in the culture medium was also potentiated by TGF-beta1, although the intracellular content of BDNF was nearly unchanged. The enhancement of BDNF mRNA expression was suppressed by the co-presence of decorin, a small TGF-beta-binding proteoglycan that inhibits the biological activities of TGF-betas. mRNA expression of full-length TrkB, the bioactive high-affinity receptor for BDNF, was also upregulated after treatment with TGF-beta1. These observations suggest that: 1) TGF-beta1 potentiates BDNF/TrkB autocrine or local paracrine system; and 2) the neurotrophic activity of TGF-beta1 is partly responsible for the BDNF induced by TGF-beta1 itself. To test this latter possibility, we examined the neuronal survival activity of TGF-beta1 with or without K252a, a selective inhibitor of Trk family tyrosine kinases. TGF-beta1 significantly enhanced neuronal survival, but the co-presence of K252a completely suppressed the activity, demonstrating the involvement of Trk receptor signaling in TGF-beta1-mediated neuronal survival in cultured rat cortical neurons. These results seem to be in line with recent findings by other investigators that some neurotrophic factors including BDNF require TGF-betas as a cofactor to exert their neurotrophic activities.


Subject(s)
Brain-Derived Neurotrophic Factor/metabolism , Central Nervous System/embryology , Gene Expression Regulation, Developmental/physiology , Neurons/metabolism , Receptor, trkB/genetics , Transforming Growth Factor beta/metabolism , Up-Regulation/physiology , Animals , Autocrine Communication/drug effects , Autocrine Communication/physiology , Brain-Derived Neurotrophic Factor/drug effects , Brain-Derived Neurotrophic Factor/genetics , Carbazoles/pharmacology , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Survival/drug effects , Cell Survival/physiology , Cells, Cultured , Central Nervous System/cytology , Central Nervous System/metabolism , Decorin , Enzyme Inhibitors/pharmacology , Extracellular Matrix Proteins , Female , Fetus , Gene Expression Regulation, Developmental/drug effects , Indole Alkaloids , Neurons/cytology , Neurons/drug effects , Pregnancy , Proteoglycans/metabolism , Proteoglycans/pharmacology , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Rats , Rats, Wistar , Time Factors , Transforming Growth Factor beta/pharmacology , Transforming Growth Factor beta1 , Up-Regulation/drug effects
20.
J Neurosci Res ; 65(3): 228-35, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11494357

ABSTRACT

Fibroblast growth factor-2 (FGF-2) was injected into mouse cerebral ventricles at embryonic day (E) 14 in utero and its effects on developing brain morphology and expression of various cell- or differentiation-associated protein markers in the cerebral cortex were examined. High doses of FGF-2 (200 or 300 ng) caused encephalic alternations such as deformation of the calvarium, enlargement of the ventricular spaces, and thinning of the cerebral cortex. There was no gross abnormality in the alignment of the cerebral neuronal layers, however, both cell number and cell density of the upper layers (II/III) and the lower layers (IV-VI) of the cerebral cortex were increased. Brain-derived neurotrophic factor (BDNF), tyrosine hydroxylase, nestin, and microtubule-associated protein 2 were aberrantly or ectopically expressed in the deep areas of the cerebral cortex. A substantial number of these cells coexpressed these antigens. These observations demonstrate that a subpopulation of neurons in the cortical deep layer abnormally differentiated or partly sustained their immature state following a single administration of FGF-2 at E14. Developmental analysis of localization of BDNF-positive cells suggested that the abnormality started around P5. Furthermore, cell migration was not affected by FGF-2 administration. FGF-2 seems to play predominant roles in the proliferation of neuronal precursors and in neuronal differentiation in the developing mouse cerebral cortex even at relatively late stages of brain neurogenesis.


Subject(s)
Cerebral Cortex/drug effects , Fibroblast Growth Factor 2/pharmacology , Hydrocephalus/chemically induced , Neurons/pathology , Animals , Biomarkers , Brain-Derived Neurotrophic Factor/analysis , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Movement , Cerebral Cortex/abnormalities , Cerebral Cortex/embryology , Cerebral Cortex/pathology , Fibroblast Growth Factor 2/administration & dosage , Fibroblast Growth Factor 2/physiology , Gestational Age , Hydrocephalus/pathology , Injections, Intraventricular , Intermediate Filament Proteins/analysis , Mice , Mice, Mutant Strains , Microtubule-Associated Proteins/analysis , Nerve Tissue Proteins/analysis , Nestin , Tyrosine 3-Monooxygenase/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...